Eastgate Biotech (ETBI) Stock Statistics & Valuation Metrics
Total Valuation
Eastgate Biotech has a market cap or net worth of $11.29M. The enterprise value is $10.67T.
- Market Cap
- $11.29M
- Enterprise Value
- $10.67T
Share Statistics
Eastgate Biotech has 2,057,546,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,057,546,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.01%
Financial Efficiency
Eastgate Biotech’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is 63.23%.
- Return on Equity (ROE)
- 0.37
- Return on Assets (ROA)
- -2.78
- Return on Invested Capital (ROIC)
- 63.23%
- Return on Capital Employed (ROCE)
- 0.34
- Revenue Per Employee
- 49.87K
- Profits Per Employee
- -1.77M
- Employee Count
- 2
- Asset Turnover
- 0.08
- Inventory Turnover
- 2.26
Valuation Ratios
The current PE Ratio of Eastgate Biotech is -2.63. Eastgate Biotech’s PEG ratio is -0.38.
- PE Ratio
- -2.63
- PS Ratio
- 103.15
- PB Ratio
- -0.98
- Price to FCF
- 170.94
- Price to Operating Cash Flow
- 83.73
- PEG Ratio
- -0.38
Income Statement
In the last 12 months, Eastgate Biotech had revenue of 99.73K and earned -3.54M in profits. Earnings per share was 0.00.
- Revenue
- 99.73K
- Gross Profit
- -110.08K
- Operating Income
- -3.27M
- Pretax Income
- -3.54M
- Net Income
- -3.54M
- EBITDA
- -3.10M
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was -1.75M and capital expenditures -52, giving a free cash flow of -1.75M billion.
- Operating Cash Flow
- -1.75M
- Free Cash Flow
- -1.75M
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Eastgate Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.59%
- Earnings Yield
- -37.21%
Stock Price Statistics
- Beta
- -1439.27
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Eastgate Biotech as a current ratio of 0.01, with Debt / Equity ratio of -46.53%
- Current Ratio
- 0.01
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.31
- Net Debt to EBITDA
- -1.45
- Interest Coverage Ratio
- -12.10
Taxes
In the past 12 months, Eastgate Biotech has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Eastgate Biotech EV to EBITDA ratio is -4.77, with an EV/FCF ratio of 245.62.
- EV to Sales
- 148.22
- EV to EBITDA
- -4.77
- EV to Free Cash Flow
- 245.62
- EV to Operating Cash Flow
- 129.95
Balance Sheet
Eastgate Biotech has $4,911.00 in cash and marketable securities with $3.08M in debt, giving a net cash position of -$3.07M billion.
- Cash & Marketable Securities
- $4,911.00
- Total Debt
- $3.08M
- Net Cash
- -$3.07M
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- ―
Margins
Gross margin is -110.37%, with operating margin of -3282.39%, and net profit margin of -3553.67%.
- Gross Margin
- -110.37%
- Operating Margin
- -3282.39%
- Pretax Margin
- -3553.67%
- Net Profit Margin
- -3553.67%
- EBITDA Margin
- -3107.18%
- EBIT Margin
- -3282.39%
Analyst Forecast
The average price target for Eastgate Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
